1 therapies2020-04-22T15:04:35+00:00

At-home
treatment of depression and chronic pain

Sooma tDCS™ is a medical device used by healthcare professionals worldwide. It has acquired e.g. CE, Health Canada, MDA, HSA, TGA and COFEPRIS approvals. The devices are manufactured in Finland under ISO 13485.

Healthcare professional – Request a quote >

How it works

The success of Sooma therapies is built on our Sooma tDCS™ device, which is a portable stimulation unit with industry leading ease of use. With Comfort accessories, the stimulation is provided with unparalleled patient comfort and accuracy. Our cloud-based Sooma Online platform enables a healthcare professional to stay in control of the therapy even when it is applied at patients’ home.

One treatment session takes 20 to 30 minutes and it is repeated once-a-day for several weeks.

Check out the latest white paper (pdf)

News and updates

403, 2020

Sooma Medical awarded EUR 1.2M agreement with VSSHP

Sooma Medical awarded EUR 1.2M agreement with VSSHP The Hospital District of Southwest Finland (VSSHP) has entered into a procurement agreement with Sooma Oy for the procurement of direct current stimulation devices (tDCS). The contracts value is approximately EUR 1.2 million and covers the years 2020-2021 with the option to extend until 2024. The contract was awarded after [...]

1812, 2019

Sooma Closes an Investment Round of Over 1.2 Million EUR

Sooma Closes an Investment Round of Over 1.2 Million EUR Sooma Oy, a Finnish medical device company developing non-invasive brain stimulation devices for treatment of neurological and psychiatric disorders, works with Finnish and Italian Angels members to secure a new investment of 1.0m Euro in equity along with a 250k Euro grant by Business Finland. Since its establishment [...]

Meet us at the following conferences and events

Woman sitting on a pier with Sooma hat

Frequently asked questions

The effect of Sooma therapies are based on subtle adjustments of the brain function using a small electrical current. The therapy is targeted to the relevant neuronal pathways e.g. dorsolateral prefrontal cortex for depression in order to achieve a treatment response.

The main changes following the therapy happen at the cortical level of the brain and can be detected with e.g. EEG and fMRI. Recently, also changes in the deep brain regions have also been detected by the use of implanted electrodes.

Sooma therapies are provided by a prescription only. They can be used to augment medication or psychotherapy, or as a monotherapy in first-line treatment. Patients who do not get adequate response from medication, or have trouble tolerating them, may benefit significantly from Sooma therapies.

There are no serious side-effects reported in 20 years of scientific study. The main side-effects are local and transient such as skin itching, mild headache or redness under the treatment area.

Sooma therapies are contraindicated from patients with

  1. Metal implants inside the skull
  2. Cardiac pacemakers
  3. Acute eczema or broken skin in the intended stimulation area

Sooma therapies are widely available around the world. First, you must be evaluated by a doctor to ensure that this is a safe and appropriate treatment for you. If your doctor is not familiar with Sooma therapies, you may request us to get in contact with your doctor by pressing “Contact Us”.

References

  1. Sooma Treatment Outcomes (2018). Available online: https://soomamedical.com/blog/treatment-outcomes-2/
  2. Zhu CE et al. Effiectiveness and safety of transcranial direct current stimulation in fibromyalgia: A systematic review and meta-analysis. J Rehabil Med. 2017 Jan 19;49(1):2-9.
  3. Cruccu G et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol. 2016 Oct;23(10):1489-99.
  4. Bikson M, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-61.
Logo of CE-marking
Quality Management System (ISO 13485) logo
Go to Top